Key statistics
As of last trade BridgeBio Pharma Inc (2CL:MUN) traded at 57.02, -15.75% below its 52-week high of 67.68, set on Jan 23, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 57.02 |
|---|---|
| High | 57.02 |
| Low | 57.02 |
| Bid | 57.34 |
| Offer | 58.16 |
| Previous close | 55.08 |
| Average volume | 1.01k |
|---|---|
| Shares outstanding | 192.71m |
| Free float | 170.38m |
| P/E (TTM) | -- |
| Market cap | 13.11bn USD |
| EPS (TTM) | -4.19 USD |
Data delayed at least 15 minutes, as of Feb 09 2026 07:00 GMT.
More ▼
Announcements
- CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
- BridgeBio to Participate in the J.P. Morgan Healthcare Conference
- BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio to Participate in December Investor Conferences
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
More ▼
